UniQure Moves Toward Accelerated Approval Path For AMT-130 After FDA Signals Support; Stock Up

uniQure said regulators indicated the three-year analysis from its Phase I/II study would be acceptable as the primary foundation for a BLA submission for AMT-130. The feedback from the recent Type B meeting reduces a key regulatory uncertainty for the gene therapy program and supports the path toward filing. The news is constructive for QURE, though it remains a development-stage biotech with execution risk.

Analysis

uniQure said regulators indicated the three-year analysis from its Phase I/II study would be acceptable as the primary foundation for a BLA submission for AMT-130. The feedback from the recent Type B meeting reduces a key regulatory uncertainty for the gene therapy program and supports the path toward filing. The news is constructive for QURE, though it remains a development-stage biotech with execution risk.